Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Symbiotec Pharmalab Ltd (SYMBIOTEC)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544889 NSE: SYMBIOTEC Pharmaceuticals & Drugs | Small Cap | Symbiotec Pharmalab Share Price
₹1,133.45 -4.60 (-0.40%)
As on 11-Sep'26 16:59
Symbiotec Pharmalab Ltd (SYMBIOTEC)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544889 NSE: SYMBIOTEC Pharmaceuticals & Drugs | Small Cap | Symbiotec Pharmalab Share Price
₹1,133.45 -4.60 (-0.40%)
As on 11-Sep'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹7,283 Cr.
Current Price
₹1,133.5
52-Week Low / High
₹934 / 1,194
TTM EPS
₹17.1
TTM Sales
₹869 Cr.
Book Value per Share
₹231.2
P/E Ratio
66.27
Industry PE
54.2
Price to Book (P/B)
4.90
Price to Sales (P/S)
8.38
EV/EBITDA
31.69
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
11.22%
Outperforms industry median
Return on Capital Employed (ROCE)
12.41%
Outperforms industry median
Return on Assets (ROA)
6.54%
Operating Profit Margin
27.7%
Net Profit Margin
12.64%
Gross Profit Margin
24.5%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
19.52%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
17.73%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
13.54%
Asset Quality
Promoter Holding
33.28%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹1,473 Cr.
Equity
₹12.9 Cr.
Face Value
₹2
All Time Low / High
₹933.80 / 1193.90
Check Before You Invest
Quality
Somewhat GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Weak
Is Symbiotec Pharmalab Ltd a good quality company?
Symbiotec Pharmalab Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Symbiotec Pharmalab Ltd performance compare with that of its Peers?
Revenue growth of Symbiotec Pharmalab Ltd vs industry peers?
Symbiotec Pharmalab Ltd revenue CAGR is 6.55%, compared to the industry median CAGR of 0.00%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Symbiotec Pharmalab Ltd?
Promoters hold 33.28% of the Symbiotec Pharmalab Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Symbiotec Pharmalab Ltd over the last decade?
Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Symbiotec Pharmalab Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 16.2% | 13.4% | 14.7% | 15.1% | 14.5% | 16.9% | 29.1% | 11.9% | 0% | 15.8% | - |
| Value Creation Index ⓘ | NA | NA | 0.1 | 0.1 | 0.1 | 0.3 | 1.2 | -0.1 | -1.0 | 0.2 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 389 | 419 | 438 | 410 | 528 | 531 | 623 | 634 | 564 | 674 | 674 |
| Sales YoY Gr. | - | 7.6% | 4.6% | -6.4% | 28.9% | 0.7% | 17.3% | 1.8% | -11.1% | 19.5% | - |
| Adj EPS ⓘ | 6 | 5.3 | 8.5 | 7.9 | 8.9 | 13.3 | 24.5 | 11.3 | 4.4 | 15.6 | 13.8 |
| YoY Gr. | - | -11.6% | 60.7% | -6.2% | 12.6% | 48.8% | 84.4% | -54% | -61.4% | 258.3% | - |
| BVPS (₹) ⓘ | 45 | 50 | 61.1 | 68.9 | 77.8 | 91 | 115.8 | 127.1 | 123.1 | 139.2 | 0 |
| Adj Net Profit ⓘ | 32.3 | 28.6 | 45.9 | 43.1 | 48.8 | 72.7 | 134 | 61.7 | 23.9 | 85.4 | 89 |
| Cash Flow from Ops. ⓘ | 28.5 | 19.2 | 52.3 | 48.3 | 43.7 | 109 | 158 | 23.5 | 93.4 | 147 | - |
| Debt/CF from Ops. ⓘ | 6.5 | 10.3 | 3.3 | 3.2 | 3.5 | 1.1 | 0.3 | 2.7 | 1.2 | 0.4 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 6.3% | 5% | 2.7% | 19.5% | ||||
| Adj EPS ⓘ | 11.3% | 11.8% | -13.9% | 258.3% | ||||
| BVPSⓘ | 13.4% | 12.4% | 6.3% | 13.1% | ||||
| Share Price | - | - | - | - | ||||
Key Financial Parameters ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 14.1 | 11.1 | 15.2 | 12.2 | 12.2 | 15.7 | 23.7 | 9.3 | 3.5 | 11.9 | 19.9 |
| Op. Profit Mgn % ⓘ | 17 | 17.7 | 19.4 | 22.5 | 18.9 | 22.5 | 32.5 | 16.6 | 14.7 | 21.3 | NAN |
| Net Profit Mgn % ⓘ | 8.3 | 6.8 | 10.5 | 10.5 | 9.3 | 13.7 | 21.5 | 9.7 | 4.2 | 12.7 | 13.2 |
| Debt to Equity ⓘ | 0.8 | 0.7 | 0.5 | 0.4 | 0.4 | 0.2 | 0.1 | 0.1 | 0.2 | 0.1 | - |
| Working Cap Days ⓘ | 163 | 198 | 216 | 246 | 231 | 260 | 221 | 246 | 316 | 326 | 0 |
| Cash Conv. Cycle ⓘ | 56 | 84 | 100 | 135 | 127 | 136 | 101 | 137 | 179 | 112 | 0 |
Valuation of Symbiotec Pharmalab - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 438 | 410 | 528 | 530 | 633 | 682 | 567 | 716 | 752 | 869 |
| Operating Expenses ⓘ + | 373 | 347 | 455 | 430 | 438 | 550 | 497 | 544 | 549 | 630 |
| Operating Profit ⓘ | 65 | 62 | 73 | 101 | 195 | 131 | 70 | 172 | 203 | 239 |
| Operating Profit Margin (%) | 14.8% | 15.2% | 13.9% | 19.0% | 30.8% | 19.3% | 12.3% | 24.0% | 27.0% | 27.5% |
| Other Income ⓘ + | 7 | 7 | 4 | 2 | 7 | 3 | 6 | 7 | 4 | 3 |
| Interest ⓘ | 19 | 18 | 18 | 11 | 7 | 3 | 8 | 8 | 17 | 26 |
| Depreciation ⓘ | 18 | 20 | 20 | 21 | 22 | 26 | 29 | 39 | 43 | 53 |
| Profit Before Tax ⓘ | 34 | 32 | 39 | 71 | 173 | 105 | 38 | 131 | 147 | 153 |
| Tax ⓘ | 4 | 18 | 17 | 18 | 48 | 28 | 15 | 31 | 50 | 43 |
| Profit After Tax | 30 | 14 | 22 | 53 | 124 | 77 | 23 | 100 | 97 | 110 |
| PAT Margin (%) | 6.9% | 3.3% | 4.2% | 10.0% | 19.6% | 11.3% | 4.2% | 14.0% | 12.9% | 12.6% |
| Adjusted EPS (₹) | 5.6 | 2.6 | 3.9 | 8.8 | 22.6 | 14.2 | 4.3 | 18.3 | 17.7 | 17.5 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 308 | 322 | 349 | 397 | 521 | 599 | 622 | 715 | 811 | 1,149 | |
| Debt + | 154 | 133 | 144 | 117 | 46 | 65 | 217 | 246 | 481 | 356 | |
| Minority Interest | 0 | 0 | 0 | -0 | 0 | -0 | -0 | -0 | -0 | -0 | |
| Trade Payables | 83 | 70 | 131 | 111 | 114 | 89 | 87 | 228 | 88 | 138 | |
| Others Liabilities ⓘ | 51 | 84 | 64 | 50 | 88 | 63 | 65 | 107 | 199 | 138 | |
| Total Liabilities ⓘ | 596 | 609 | 688 | 676 | 768 | 815 | 990 | 1,295 | 1,580 | 1,781 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 239 | 228 | 224 | 230 | 261 | 280 | 299 | 411 | 402 | 1,084 | |
| CWIP ⓘ | 1 | 7 | 13 | 31 | 28 | 40 | 182 | 208 | 568 | 64 | |
| Investments ⓘ | 81 | 53 | 44 | 9 | 5 | 5 | 5 | 4 | 1 | 4 | |
| Inventories | 128 | 128 | 216 | 231 | 226 | 246 | 244 | 336 | 261 | 237 | |
| Trade Receivables | 110 | 123 | 128 | 106 | 118 | 144 | 112 | 126 | 176 | 198 | |
| Cash Equivalents | 5 | 13 | 9 | 37 | 49 | 11 | 6 | 8 | 26 | 10 | |
| Others Assets ⓘ | 31 | 57 | 54 | 32 | 82 | 90 | 142 | 203 | 145 | 183 | |
| Total Assets ⓘ | 596 | 609 | 688 | 676 | 768 | 815 | 990 | 1,295 | 1,580 | 1,781 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 41 | 25 | 23 | 88 | 174 | 18 | 69 | 188 | 47 | 175 |
| Cash Flow From Investing Activity ⓘ + | 3 | 13 | -13 | -41 | -96 | -32 | -220 | -206 | -307 | -227 |
| Cash Flow From Financing Activity ⓘ + | -44 | -32 | -14 | -42 | -79 | 15 | 146 | 22 | 278 | 36 |
| Net Cash Flow ⓘ | 0 | 6 | -4 | 4 | -1 | 1 | -5 | 3 | 19 | -16 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 9.78 | 4.29 | 6.57 | 14.15 | 27.06 | 13.81 | 3.85 | 14.97 | 12.69 | 11.22 |
| ROCE (%) | 11.14 | 10.37 | 11.52 | 16.02 | 33.04 | 17.64 | 6.18 | 15.42 | 14.14 | 12.41 |
| Asset Turnover Ratio | 0.75 | 0.68 | 0.81 | 0.78 | 0.88 | 0.86 | 0.64 | 0.63 | 0.53 | 0.52 |
| PAT to CFO Conversion(x) | 1.37 | 1.79 | 1.05 | 1.66 | 1.4 | 0.23 | 3 | 1.88 | 0.48 | 1.59 |
| Working Capital Days | ||||||||||
| Receivable Days | 90 | 103.90 | 86.60 | 80.50 | 64.70 | 70 | 81.10 | 60 | 72.30 | 77.50 |
| Inventory Days | 104.60 | 114.10 | 119 | 153.80 | 131.60 | 126.20 | 155.30 | 146.20 | 143.30 | 103.50 |
| Payable Days | 131.10 | 137.30 | 120.60 | 171.60 | 153.60 | 104.90 | 109.70 | 178.60 | 194 | 131.20 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Symbiotec Pharmalab Ltd FAQs
The current trading price of Symbiotec Pharmalab on 11-Sep-2026 16:59 is ₹1,133.5.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 10-Sep-2026 the market cap of Symbiotec Pharmalab stood at ₹7,283.1 Cr
The latest P/E ratio of Symbiotec Pharmalab as of 10-Sep-2026 is 81.88.
The latest P/B ratio of Symbiotec Pharmalab as of 10-Sep-2026 is 0.00.
The 52-week high of Symbiotec Pharmalab is ₹1,193.9 and the 52-week low is ₹933.8.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Symbiotec Pharmalab is ₹674 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Symbiotec Pharmalab Ltd is a average quality company.
The key valuation ratios of Symbiotec Pharmalab Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Symbiotec Pharmalab Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Symbiotec Pharmalab Ltd
Symbiotec Pharmalab, incorporated on September 20, 2002, is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms - organic chemistry, biotechnology and complex injectables. It has leveraged its deep capabilities across organic chemistry, biotechnology, and complex injectables to operate as a contract development and manufacturing organisation (CDMO) variably for specialty pharmaceutical and nutraceutical companies globally, offering products and services across the three platforms in which it also manufactures its own products.
Its organic chemistry capabilities include flow chemistry, hydrogenation, and photochemistry, while biotechnology capabilities include biosynthesis and biotransformation, and recombinant biologics, including Glucagon-like Peptide-1 (GLP-1) and Insulins. Further, its complex injectables capabilities include double-chamber vials, double-chamber bags and double-chamber syringes. It has a robust product portfolio of corticosteroid and steroidal-hormone APIs that are supplied globally, including Hydrocortisones, Betamethasones, Methylprednisolones, Progesterones, Estrogens and Testosterones, which are used extensively in critical care setups, as well as across chronic therapeutic areas such as respiratory, dermatology, pain management, oncology and gynaecology.
Its broad capabilities are enabled by conversion of commodity plant-based derivative inputs (farm/ microbe-to-pharmacy approach) and work with diverse microbial strains such as bacteria, fungi, yeast and algae to convert into high value steroid and hormonal pre-cursors. This supports backward integration and underpins its ‘farm/microbe-to-pharmacy’ approach. This integration allows the company to make strategic, cost-effective ‘make versus buy’ decisions, thereby reducing external dependence for sourcing intermediates from other geographies.
Business area of the company
The company is engaged in the business of manufacturing and selling of Active Pharmaceuticals Ingredients (API) and Intermediates. It caters to both domestic and international markets.
Products and services of the company
APIs
- Corticosteroid APIs
- Steroidal-Hormone APIs
- Classical Fermentation and Differentiated APIs
Complex Injectables
CDMO services
Awards, accreditations and recognition
- 2017: Received a letter of honour by the Collector - Dhar, Madhya Pradesh for the purpose of discharging corporate social responsibility by making selected government schools / hostels of the district, resource rich by developing infrastructure, creating environment and fulfilling academic requirements.
- 2020: Received a letter of honour by the Collector - Dhar, Madhya Pradesh for discharging the company’s corporate social responsibility by actively contributing to the availability of antidotes, sanitizers, PPE kits, distribution of food packets to migrant labours, availability of transport for effective support of civil security and administration during COVID-19 at the district hospital of Dhar and the primary community and health centres in Dhar.
- 2021: Awarded a certificate of registration for ‘ISO 14001:2015’ for the Pithampur Facility.
- 2021: Awarded a certificate of registration for ‘ISO 14001:2018’ for the Pithampur Facility.
- 2023: Awarded a certificate of appreciation by the U.S. Pharmacopeial Convention.
- 2024: Received a bronze top 35% eco vadis sustainability rating by Eco Vadis.
- 2024: Awarded a certificate of registration for ‘ISO 45001:2018 for the Pithampur Facility and Rau Facility.
- 2024: Awarded a certificate of registration for ‘ISO 14001:2015 for the Rau Facility.
- 2025: Awarded an international safety award merit by the British Safety Council International Safety Awards 2025.
- 2025: Awarded a pass certificate by the British Safety Council International Safety Awards 2025.
History and milestones
- 2004: Commenced production of APIs at the Rau Facility.
- 2007: Investment by late Rakesh Jhunjhunwala in the company.
- 2009: Received a letter stating that the Rau Facility meets an acceptable state of compliance with cGMP by U.S. FDA.
- 2010: Commenced production of APIs including hormone synthesis at the Pithampur Facility.
- 2010: Commissioned a 5 KL biotech plant at the Pithampur Facility.
- 2010: Investment by Franklin Templeton Asset Management (India) Private Limited in the company.
- 2012: Received a letter stating that the Pithampur Facility meets an acceptable state of compliance with the cGMP from the U.S. FDA.
- 2013: Investment by Actis Medal Sports Limited in the company.
- 2013: Commissioned a 35 KL fermentation project at the Pithampur Facility.
- 2018: Investment by India Business Excellence Fund- III and Rosewood Investments in the company.
- 2021: Expansion of a sterile plant at the Rau Facility.
- 2023: Launched classical fermentation-based APIs at the Pithampur Facility.
- 2025: Commissioned a complex injectables facility at the Mhow Facility.
- 2025: Commissioned a 400 KL biomanufacturing facility at the Ujjain Facility.
You have 48 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
